These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 25446815)

  • 1. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration.
    Gao HJ; Zhao MC; Zhang YJ; Zhou DS; Xu L; Li GB; Chen MS; Liu J
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1151-62. PubMed ID: 25446815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma.
    Ohno A; Yorita K; Haruyama Y; Kondo K; Kato A; Ohtomo T; Kawaguchi M; Marutuska K; Chijiiwa K; Kataoka H
    Liver Int; 2014 Jul; 34(6):942-52. PubMed ID: 24433439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy.
    Chen HL; OuYang HY; Le Y; Jiang P; Tang H; Yu ZS; He MK; Tang YQ; Shi M
    Cancer Med; 2018 Nov; 7(11):5339-5350. PubMed ID: 30306706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of monocarboxylate transporter 4 in patients with esophageal squamous cell carcinoma.
    Cheng B; Chen X; Li Y; Huang X; Yu J
    Oncol Rep; 2018 Nov; 40(5):2906-2915. PubMed ID: 30226548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery.
    Huang M; Wang L; Chen J; Bai M; Zhou C; Liu S; Lin Q
    Int J Oncol; 2016 May; 48(5):2144-54. PubMed ID: 26984380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
    Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
    Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis.
    Kim HK; Lee I; Bang H; Kim HC; Lee WY; Yun SH; Lee J; Lee SJ; Park YS; Kim KM; Kang WK
    Mol Cancer Ther; 2018 Apr; 17(4):838-848. PubMed ID: 29483215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
    Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
    Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients.
    Bai B; Lin Y; Hu J; Wang H; Li L; Zhao S; Zhang J; Meng W; Yue P; Bai Z; Li X
    Oncol Rep; 2019 Mar; 41(3):1539-1548. PubMed ID: 30747220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma.
    Zhang XF; Chao J; Pan QZ; Pan K; Weng DS; Wang QJ; Zhao JJ; He J; Liu Q; Jiang SS; Chen CL; Zhang HX; Xia JC
    Oncotarget; 2015 Dec; 6(38):40920-33. PubMed ID: 26506518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
    Cao YW; Liu Y; Dong Z; Guo L; Kang EH; Wang YH; Zhang W; Niu HT
    Urol Oncol; 2018 Jun; 36(6):311.e15-311.e25. PubMed ID: 29657088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
    Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
    BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hornerin promotes tumor progression and is associated with poor prognosis in hepatocellular carcinoma.
    Fu SJ; Shen SL; Li SQ; Hua YP; Hu WJ; Guo B; Peng BG
    BMC Cancer; 2018 Aug; 18(1):815. PubMed ID: 30103712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA CARLo-5 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients.
    Wang F; Xie C; Zhao W; Deng Z; Yang H; Fang Q
    Clin Exp Med; 2017 Feb; 17(1):33-43. PubMed ID: 26433964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monocarboxylate Transporters MCT1 and MCT4 Regulate Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells.
    Kong SC; Nøhr-Nielsen A; Zeeberg K; Reshkin SJ; Hoffmann EK; Novak I; Pedersen SF
    Pancreas; 2016 Aug; 45(7):1036-47. PubMed ID: 26765963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulated TRIO expression correlates with a malignant phenotype in human hepatocellular carcinoma.
    Wang B; Fang J; Qu L; Cao Z; Zhou J; Deng B
    Tumour Biol; 2015 Sep; 36(9):6901-8. PubMed ID: 25851347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas.
    Yorita K; Ohno A; Nishida T; Kondo K; Ohtomo T; Kataoka H
    BMC Res Notes; 2019 Nov; 12(1):741. PubMed ID: 31706332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monocarboxylate transporter 4 facilitates cell proliferation and migration and is associated with poor prognosis in oral squamous cell carcinoma patients.
    Zhu J; Wu YN; Zhang W; Zhang XM; Ding X; Li HQ; Geng M; Xie ZQ; Wu HM
    PLoS One; 2014; 9(1):e87904. PubMed ID: 24498219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma.
    Wang JH; Zhong XP; Zhang YF; Wu XL; Li SH; Jian PE; Ling YH; Shi M; Chen MS; Wei W; Guo RP
    Cell Death Dis; 2017 Sep; 8(9):e3043. PubMed ID: 28880268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.